Drug Profile

QTX 125

Alternative Names: HiD-21; HiD21 for injection; QTX-125

Latest Information Update: 24 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quimatryx
Developer HiDiamond; Quimatryx
Class Amides; Antineoplastics; Benzamides; Furans; Oximes; Phenols; Pyrroles; Small molecules
Mechanism of Action HDAC6 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Haematological malignancies; Solid tumours

Most Recent Events

02 Mar 2026 Chemical structure information added.
23 Feb 2026 Quimatryx entered into a strategic partnership with the HiDiamond to accelerate the development of its QTX125
23 Feb 2026 Quimatryx has patent protection for QTX 125 in USA, Europe, China, Mexico, Japan and Russia before February 2026 (Quimatryx pipeline, February 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com